Evidence map›Paper›PMID 26338727›Full record

ReviewGut2016

The gut microbiota and host health: a new clinical frontier.

Julian R Marchesi, David H Adams, Francesca Fava, Gerben D A Hermes, Gideon M Hirschfield, Georgina Hold, Mohammed Nabil Quraishi, James Kinross, Hauke Smidt, Kieran M Tuohy and 3 more

3 registry-linked trialsAbstract readReview
In one paragraph

Review in Gut, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1,113 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,113citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03593941 completednot on this mapstarted 2018, after this paper: background citation

Ageing Gut Brain Interactions

TypeobservationalSponsorUniversity of AberdeenRan2018 to 2020Enrolled60ConditionsDementia AlzheimersArmsStandard Diet
NCT04204005 nacompletednot on this mapstarted 2017, after this paper: background citation

Probiotics-addicted Low-protein Diet for Microbiota Modulation in Patients With Advanced Chronic Kidney Disease (ProLowCKD): a Protocol of Placebo-controlled Randomized Trial

TypeinterventionalSponsorProbiotical S.p.A.Ran2017 to 2020Enrolled50ConditionsRenal Failure ChronicArmsProbiotics
NCT05603403 phase4completednot on this mapstarted 2022, after this paper: background citation

Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

TypeinterventionalSponsorAzidus BrasilRan2022 to 2023Enrolled150ConditionsSigns and Symptoms, DigestiveArmsProbiatop, Placebo
3 · Its place in the literature

Who cites it

1,113 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Trial
  15. Trial
  16. Gut microbes · 2026
    Article
  17. Observational
  18. Article
  19. Review
  20. Review

1,053 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julian R MarchesiSchool of Biosciences, Museum Avenue, Cardiff University, Cardiff, UK Centre for Digestive and Gut Health, Imperial College London, London, UK.
David H AdamsNIHR Biomedical Research Unit, Centre for Liver Research, University of Birmingham, Birmingham, UK.
Francesca FavaNutrition and Nutrigenomics Group, Department of Food Quality and Nutrition, Research and Innovation Centre, Trento, Italy.
Gerben D A HermesLaboratory of Microbiology, Wageningen University, Wageningen, The Netherlands Top Institute Food and Nutrition (TIFN), Wageningen, The Netherlands.
Gideon M HirschfieldNIHR Biomedical Research Unit, Centre for Liver Research, University of Birmingham, Birmingham, UK.
Georgina HoldDivision of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen, Institute of Medical Sciences, Aberdeen, UK.
Mohammed Nabil QuraishiNIHR Biomedical Research Unit, Centre for Liver Research, University of Birmingham, Birmingham, UK.
James KinrossSection of Computational and Systems Medicine, Faculty of Medicine, Imperial College London, London, UK.
Hauke SmidtLaboratory of Microbiology, Wageningen University, Wageningen, The Netherlands.
Kieran M TuohyNutrition and Nutrigenomics Group, Department of Food Quality and Nutrition, Research and Innovation Centre, Trento, Italy.
Linda V ThomasYakult UK Limited, Middlesex, UK.
Erwin G ZoetendalLaboratory of Microbiology, Wageningen University, Wageningen, The Netherlands Top Institute Food and Nutrition (TIFN), Wageningen, The Netherlands.
Ailsa HartIBD Unit, St Mark's Hospital and Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last 10-15 years, our understanding of the composition and functions of the human gut microbiota has increased exponentially. To a large extent, this has been due to new 'omic' technologies that have facilitated large-scale analysis of the genetic and metabolic profile of this microbial community, revealing it to be comparable in influence to a new organ in the body and offering the possibility of a new route for therapeutic intervention. Moreover, it might be more accurate to think of it like an immune system: a collection of cells that work in unison with the host and that can promote health but sometimes initiate disease. This review gives an update on the current knowledge in the area of gut disorders, in particular metabolic syndrome and obesity-related disease, liver disease, IBD and colorectal cancer. The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidence relating to antibiotics, probiotics, prebiotics, polyphenols and faecal microbiota transplantation.

Indexed as

Health StatusAnimalsAutoimmune DiseasesBacteriaColitis, UlcerativeCrohn DiseaseGastrointestinal MicrobiomeHumansInflammatory Bowel DiseasesLiver DiseasesLiver Diseases, AlcoholicNon-alcoholic Fatty Liver DiseaseObesityPolyphenolsPouchitisPrebioticsPolyphenolsPrebioticsINTESTINAL BACTERIA

Identifiers

PMID26338727
PMCPMC4752653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.